Evidence Compare
Select 2–4 articles to compare side-by-side.
HFpEF — example loaded
| Field | Article 1 | Article 2 | Article 3 |
|---|---|---|---|
| Drug | Empagliflozin 10mg | Sacubitril/Valsartan | Dapagliflozin 10mg |
| Trial | EMPEROR-Preserved | PARAGON-HF | DELIVER |
| Population | 5,988 HFpEF (EF >40%) | 4,822 HFpEF (EF ≥45%) | 6,263 HFmrEF/HFpEF |
| Primary Outcome | CV death + HFH | CV death + total HFH | CV death + worsening HF |
| HR | 0.79 (0.69-0.90) | 0.87 (0.75-1.01) | 0.82 (0.73-0.92) |
| NNT | 31 over 26 mo | Not significant | 32 over 27 mo |
| Year | 2021 | 2019 | 2022 |
| Source | NEJM | NEJM | NEJM |